Achieve Life Sciences
Committed to the development of cytisinicline as the first new Rx treatment for nicotine dependence in ~20 years.
Bothell, United States
29 employees
Post-IPO Debt
Total: $187.32M
Biotechnology, Health Care +2
General Information
Bothell, United States
BounceWatch is an independent company data service, not affiliated with Achieve Life Sciences. To contact Achieve Life Sciences, visit achievelifesciences.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
United States Market
Biotechnology
About Achieve Life Sciences
Taxonomy: Smoking Cessation, Pharmaceuticals, Global Health, Nicotine Addiction, Specialty Pharmaceutical Company, Cytisine, Preventable Death, Health Epidemic, Drug Development, Pharmaceutical Manufacturing
Funding Rounds & Investors (7)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Debt | $10.00M | 1 |
Silicon Valley Bank
|
29 Jul 2024 |
| Post IPO Equity | $124.20M | 3 |
|
29 Feb 2024 |
| Post IPO Equity | $16.50M | - |
|
25 May 2023 |
| Grant | $2.50M | 1 |
-logo.jpg){kind=logo}
|
01 Jun 2022 |
| Grant | $320.00K | 1 |
|
22 Jul 2021 |
| Post IPO Equity | $20.00M | - |
|
25 May 2021 |
| Post IPO Equity | $13.80M | - |
|
19 Dec 2019 |
Achieve Life Sciences Alternatives & Competitors
View All Alternatives
Inhaled Therapies, Instant Relief
Our mission is to treat the world’s largest preventable cause of death – smoking.
Global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
FAQ About Achieve Life Sciences
Source: BounceWatch company record for Achieve Life Sciences, https://bouncewatch.com/company/achieve-life-sciences, updated 30 December 2024. When citing, please name BounceWatch and link this page.
